Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Stem Cells. Apr 26, 2014; 6(2): 94-110
Published online Apr 26, 2014. doi: 10.4252/wjsc.v6.i2.94
“Ins” and “Outs” of mesenchymal stem cell osteogenesis in regenerative medicine
Dean T Yamaguchi
Dean T Yamaguchi, Research Service, Veteran Administration Greater Los Angeles Healthcare System and David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA 90073, United States
Author contributions: Yamaguchi DT solely contributed to this review.
Supported by Veterans Administration Merit Review Award 2 I01 BX000170-05
Correspondence to: Dean T Yamaguchi, MD, PhD, Research Service, Veteran Administration Greater Los Angeles Healthcare System and David Geffen School of Medicine at University of California at Los Angeles, 11301 Wilshire Blvd, Bldg 114, Rm 330, Los Angeles, CA 90073, United States. dean.yamaguchi@va.gov
Telephone: +1-310-2683459 Fax: +1-310-2684856
Received: October 20, 2013
Revised: January 15, 2014
Accepted: January 17, 2014
Published online: April 26, 2014
Core Tip

Core tip: When human telomerase reverse transcriptase (hTERT) transformed human mesenchymal stem cells (hMSCs) are used to prolong replicative potential and osteogenic differentiation, consideration should be given to using lower population doubling hTERT-transformed hMSCs to avoid potential oncogenesis. An inducible hTERT system may also avoid oncogenic transformation. Demonstration of in vivo bone forming capacity of hTERT-transformed cells should be used as standard in determining osteogenic differentiation of such cells rather than in vitro culture mineralization; the CD146 marker may be a suggested surface marker for hTERT-transformed hMSCs that may have the capacity to form bone in vivo. Native ECM from early population doubling hMSCs or hMSCs from a younger source may be best when seeking to extend the proliferative and differentiating potential of hMSCs from either young or older sources.